Agios Pharmaceuticals (AGIO) Net Cash Flow (2012 - 2026)

Agios Pharmaceuticals has reported Net Cash Flow for 15 years, with the latest figure at $24.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 800.63% year-over-year to $24.5 million; the trailing twelve-month figure through Mar 2026 stood at $34.6 million (up 187.03% YoY), and the FY2025 full-year result was $12.9 million, up 207.74% from the prior year.
• Net Cash Flow for Q1 2026 stood at $24.5 million, up from -$3.6 million in the prior quarter.
• The five-year high for Net Cash Flow was $169.2 million in Q3 2024, with the low at -$177.5 million in Q4 2024.
• Historically, Net Cash Flow has averaged -$5.3 million across 5 years, with a median of $2.7 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 941.1% — and 2024, when it jumped 928.66%.
• Agios Pharmaceuticals' Net Cash Flow stood at $16.8 million in 2022, then jumped by 42.01% to $23.9 million in 2023, then sank by 843.48% to -$177.5 million in 2024, then soared by 97.98% to -$3.6 million in 2025, then jumped by 783.52% to $24.5 million in 2026.
• The last three Net Cash Flow figures came in at $24.5 million (Q1 2026), -$3.6 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.